You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
NovaBridge Biosciences appointed Chuck Silberstein, M.D., M.B.A., CFA as Chief Financial Officer effective November 2, 2026, succeeding Ming (Kyler) Lei, whose resignation becomes effective October 30, 2026.
NovaBridge Biosciences reported Phase 1b givastomig results in first-line metastatic gastroesophageal adenocarcinoma: the selected 8 mg/kg dose achieved a 79% objective response rate (23/29). The company also reported FDA alignment on Phase 3 study design.
NovaBridge Biosciences reported that ongoing Phase 1 clinical-trial data for ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, were presented by ABL Bio at the European Society for Medical Oncology Congress 2026.
NovaBridge Biosciences’ majority-owned Visara entered an exclusive worldwide license, excluding Greater China, with Wuhan Hiteck Biological Pharma for VIS-102, paying $7.0 million upfront and near-term milestones plus up to $104.0 million in additional milestone payments.
